Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTEPAR vs HETRAZAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.
Treatment of ascariasis (roundworm infection),Treatment of enterobiasis (pinworm infection)
Treatment of lymphatic filariasis (Wuchereria bancrofti, Brugia malayi),Treatment of tropical pulmonary eosinophilia,Treatment of loiasis (Loa loa)
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; may be prolonged in renal impairment.
Partially metabolized in the liver; some metabolites are excreted unchanged.
Diethylcarbamazine is rapidly absorbed and extensively metabolized in the liver via N-oxidation and N-demethylation, involving multiple CYP enzymes. The major metabolite is diethylcarbamazine N-oxide.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Renal excretion of unchanged drug accounts for approximately 50-60% of elimination; the remainder is metabolized hepatically with metabolites excreted in urine. Fecal elimination is minimal (<5%).
Approximately 90% bound to plasma proteins, primarily albumin.
Protein binding is approximately 10-20%, primarily to albumin.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water.
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution.
Oral bioavailability is approximately 80-90% due to extensive absorption with minimal first-pass metabolism.
Oral bioavailability is approximately 90% due to well absorption from the gastrointestinal tract.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 25-50% of normal dose; hemodialysis: administer after dialysis.
No specific GFR-based dose modifications available; use with caution in renal impairment due to potential accumulation. Monitor for adverse effects.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: contraindicated or use with extreme caution, reduce dose by 75%.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Contraindicated.
Children: 10-20 mg/kg/day orally in 2 divided doses; maximum 750 mg/day for <10 kg, 1.5 g/day for 10-20 kg, 2.25 g/day for 20-40 kg, 3 g/day for >40 kg.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg. For children <15 kg, dosage based on 1 mg/kg initially, then increase gradually.
Elderly: initiate at lower end of dosing range; monitor renal function and adjust dose accordingly; avoid in patients with significant hepatic impairment.
Initiate at lower end of dosing range (2 mg/kg per dose) due to potential age-related decrease in renal function. Monitor closely for adverse effects.
None.
HETRAZAN is contraindicated in patients with onchocerciasis (river blindness) due to the risk of severe Mazzotti reaction, including ocular damage and encephalopathy. Treatment should not be initiated in areas where onchocerciasis is endemic or in patients with suspected onchocerciasis.
Caution in patients with epilepsy or impaired renal function; may cause neurotoxicity at high doses.
Severe allergic or inflammatory reactions (Mazzotti reaction) in patients with onchocerciasis; encephalopathy in loiasis with high microfilarial loads; ocular damage (e.g., uveitis, optic neuritis) in onchocerciasis; thrombocytopenia; aminotransferase elevations; use in pregnancy only if clearly needed.
Hypersensitivity to piperazine; patients with pre-existing neurological disorders such as epilepsy.
Onchocerciasis (active or suspected),High-grade Loa loa microfilaremia (>8000 microfilariae/m L),Hypersensitivity to diethylcarbamazine or any component of the formulation
No significant food interactions reported. Avoid alcohol as it may increase CNS side effects. Take with food if gastrointestinal upset occurs.
Grapefruit juice may inhibit CYP450 metabolism; avoid concurrent intake. Administer with food to reduce gastrointestinal distress.
ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. First trimester exposure may be associated with a slightly increased risk of congenital anomalies, though data are limited. Second and third trimester risks are not well-defined; use only if clearly needed.
Animal studies have not been conducted; no adequate human data. Use only if benefit outweighs risk. No known teratogenic effects in first trimester; limited data in second and third trimesters.
Piperazine is excreted into breast milk in small amounts. The M/P ratio is not established. The American Academy of Pediatrics considers piperazine compatible with breastfeeding, but caution is advised due to potential adverse effects in nursing infants. Use only if benefits outweigh risks.
Excreted into breast milk; M/P ratio unknown. Use with caution due to potential for adverse effects in infant.
No specific dose adjustments recommended during pregnancy. Piperazine pharmacokinetics may be altered due to increased plasma volume and renal clearance, but standard dosing is generally used. Monitor for efficacy and adverse effects.
No specific dose adjustments recommended; pharmacokinetics may be altered but data insufficient to guide changes.
ANTEPAR (piperazine) is a first-line treatment for ascariasis and enterobiasis. It causes neuromuscular paralysis in worms via GABA receptor agonism. Contraindicated in epilepsy and renal impairment. Monitor for neurotoxicity (ataxia, confusion) especially in children. Effective against both adult and immature worms; no need for laxatives.
HETRAZAN (diethylcarbamazine) is primarily used for lymphatic filariasis and loiasis; monitor for Mazzotti reaction (fever, rash, arthralgias) in high microfilarial loads; contraindicated in onchocerciasis due to severe ocular reactions; administer with food to reduce GI upset.
Take exactly as prescribed; complete full course even if symptoms improve.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Report any muscle weakness, tremors, or confusion to your doctor immediately.,For pinworm infection, all household members should be treated to prevent reinfection.,Practice strict hand hygiene and wash bed linens in hot water to reduce spread.
Take with food to minimize nausea.,Report any severe itching, rash, fever, or vision changes.,Complete full course even if symptoms improve.,Avoid grapefruit juice which may affect metabolism.,May cause dizziness or drowsiness; avoid driving if affected.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTEPAR vs HETRAZAN, answered by our medical review team.
ANTEPAR is a Anthelmintic that works by Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.. HETRAZAN is a Anthelmintic that works by Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTEPAR and HETRAZAN depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTEPAR is: Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.. The standard adult dose of HETRAZAN is: 2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTEPAR and HETRAZAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTEPAR is classified as Category C. ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. Fir. HETRAZAN is classified as Category C. Animal studies have not been conducted; no adequate human data. Use only if benefit outweighs risk. No known teratogenic effects in first trimester; limited data in second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.